Arnout Bruggeman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Arnout Bruggeman has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Santens
Department of Neurology, Ghent University Hospital, Ghent, Belgium
6 shared publications - Charysse Vandendriessche
VIB Center for Inflammation Research, Ghent, Belgium
4 shared publications - Roosmarijn E. Vandenbroucke
VIB Center for Inflammation Research, VIB, Ghent, Belgium
4 shared publications Debby Laukens
2 shared publications- Elien Van Wonterghem
VIB Center for Inflammation Research, VIB, 9052 Ghent, Belgium
2 shared publications - Griet Van Imschoot
VIB Center for Inflammation Research, VIB, 9052 Ghent, Belgium
2 shared publications
Latest Publications
- 15 November 2026
- Published by Elsevier in Brain, Behavior, and Immunity
Enduring neuroinflammation in the prefrontal cortex following chronic colitis: A role for C1q?
- 15 November 2026
- Published by Elsevier in Brain, Behavior, and Immunity
Enduring neuroinflammation in the prefrontal cortex following chronic colitis: A role for C1q?
- Open Access
- 24 June 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (3_suppl) , 17-29
Rationale and current status of fecal microbiota transplantations for Parkinson's disease
Treating a neurological disorder through the gut may seem counterintuitive, yet multiple lines of evidence highlight the gut's important role in Parkinson's disease (PD). Prodromal gastrointestinal symptoms, the presence of aggregated α-synuclein in enteric neurons, increased intestinal inflammation, and impaired epithelial barrier integrity all point to gut-level involvement in PD pathophysiology. The gut microbiome, markedly altered in individuals with PD, may be a key driver of these changes. Fecal microbiota transplantation (FMT) is currently the most effective strategy for achieving broad and durable modifications of gut microbiota composition. However, FMT is a complex, multi-step procedure requiring stringent methodological control. Modulating gut bacteria has demonstrated therapeutic potential in preclinical models of PD, and recent clinical trials have begun evaluating FMT in patients, although outcomes have been variable. In this review, we examine potential explanations for these divergent results, with a particular focus on methodological differences across trials. We also outline future directions for optimizing FMT study design in PD and discuss how these insights may guide the development of next-generation microbiota-targeted therapies.
- 24 June 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (3_suppl) , 17-29
Open AccessRationale and current status of fecal microbiota transplantations for Parkinson's disease
Treating a neurological disorder through the gut may seem counterintuitive, yet multiple lines of evidence highlight the gut's important role in Parkinson's disease (PD). Prodromal gastrointestinal symptoms, the presence of aggregated α-synuclein in enteric neurons, increased intestinal inflammation, and impaired epithelial barrier integrity all point to gut-level involvement in PD pathophysiology. The gut microbiome, markedly altered in individuals with PD, may be a key driver of these changes. Fecal microbiota transplantation (FMT) is currently the most effective strategy for achieving broad and durable modifications of gut microbiota composition. However, FMT is a complex, multi-step procedure requiring stringent methodological control. Modulating gut bacteria has demonstrated therapeutic potential in preclinical models of PD, and recent clinical trials have begun evaluating FMT in patients, although outcomes have been variable. In this review, we examine potential explanations for these divergent results, with a particular focus on methodological differences across trials. We also outline future directions for optimizing FMT study design in PD and discuss how these insights may guide the development of next-generation microbiota-targeted therapies.
- 23 September 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (6) , e213864
False-Positive MOG Antibodies in a Patient With a Slow-Progressive Intramedullary Glioma
- 23 September 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (6) , e213864
False-Positive MOG Antibodies in a Patient With a Slow-Progressive Intramedullary Glioma
- 24 July 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (1) , 261-264
Tumefactive Virchow‐Robin Spaces as a Cause of Secondary Parkinsonism
- 24 July 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (1) , 261-264
Tumefactive Virchow‐Robin Spaces as a Cause of Secondary Parkinsonism
- Open Access
- 15 August 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (10) , e16350
Functional neurological disorder in Europe: regional differences in education and health policy
Background: Functional neurological disorder (FND) is a common cause of neurological disability. Despite recent advances in pathophysiological understanding and treatments, application of this knowledge to clinical practice is variable and limited.Objective: Our aim was to provide an expert overview of the state of affairs of FND practice across Europe, focusing on education and training, access to specialized care, reimbursement and disability policies, and academic and patient‐led representation of people with FND.Methods: We conducted a survey across Europe, featuring one expert per country. We asked experts to compare training and services for people with FND to those provided to people with multiple sclerosis (MS).Results: Responses from 25 countries revealed that only five included FND as a mandatory part of neurological training, while teaching about MS was uniformly included. FND was part of final neurology examinations in 3/17 countries, unlike MS that was included in all 17. Seventeen countries reported neurologists with an interest in FND but the estimated mean ratio of FND‐interested neurologists to MS neurologists was 1:20. FND coding varied, with psychiatric coding for FND impacting treatment access and disability benefits in the majority of countries. Twenty countries reported services refusing to see FND patients. Eight countries reported an FND special interest group or network; 11 reported patient‐led organizations.Conclusions: FND is largely a marginal topic within European neurology training and there is limited access to specialized care and disability benefits for people with FND across Europe. We discuss how this issue can be addressed at an academic, healthcare and patient organization level.
- 15 August 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (10) , e16350
Open AccessFunctional neurological disorder in Europe: regional differences in education and health policy
Background: Functional neurological disorder (FND) is a common cause of neurological disability. Despite recent advances in pathophysiological understanding and treatments, application of this knowledge to clinical practice is variable and limited.Objective: Our aim was to provide an expert overview of the state of affairs of FND practice across Europe, focusing on education and training, access to specialized care, reimbursement and disability policies, and academic and patient‐led representation of people with FND.Methods: We conducted a survey across Europe, featuring one expert per country. We asked experts to compare training and services for people with FND to those provided to people with multiple sclerosis (MS).Results: Responses from 25 countries revealed that only five included FND as a mandatory part of neurological training, while teaching about MS was uniformly included. FND was part of final neurology examinations in 3/17 countries, unlike MS that was included in all 17. Seventeen countries reported neurologists with an interest in FND but the estimated mean ratio of FND‐interested neurologists to MS neurologists was 1:20. FND coding varied, with psychiatric coding for FND impacting treatment access and disability benefits in the majority of countries. Twenty countries reported services refusing to see FND patients. Eight countries reported an FND special interest group or network; 11 reported patient‐led organizations.Conclusions: FND is largely a marginal topic within European neurology training and there is limited access to specialized care and disability benefits for people with FND across Europe. We discuss how this issue can be addressed at an academic, healthcare and patient organization level.
- Top Cited PapersOpen Access
- 27 March 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 71, 102563
Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial
- 27 March 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 71, 102563
Top Cited PapersOpen AccessSafety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Cover Letter Submission: Hypotonia as an Additional Feature in a Complex Movement Disorder Caused by a Novel Mutation in the ANO3 Gene
We present the case of a patient with a complex movement disorder that could be attributed to a novel mutation in the ANO3 gene. In addition to tremor and chorea, which are known features of the clinical syndrome associated with these mutations, she had marked hypotonia. Although frequently mentioned in hyperkinetic disorders, hypotonia is ill-defined and needs a reappraisal.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessCover Letter Submission: Hypotonia as an Additional Feature in a Complex Movement Disorder Caused by a Novel Mutation in the ANO3 Gene
We present the case of a patient with a complex movement disorder that could be attributed to a novel mutation in the ANO3 gene. In addition to tremor and chorea, which are known features of the clinical syndrome associated with these mutations, she had marked hypotonia. Although frequently mentioned in hyperkinetic disorders, hypotonia is ill-defined and needs a reappraisal.
- Open Access
- 8 December 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (12) , 1864
Anti-Inflammatory Mesenchymal Stromal Cell-Derived Extracellular Vesicles Improve Pathology in Niemann–Pick Type C Disease
Niemann–Pick type C (NPC) disease is a rare neurovisceral lipid storage disease with progressive neurodegeneration, leading to premature death. The disease is caused by loss-of-function mutations either in the NPC1 or NPC2 gene which results in lipid accumulation in the late endosomes and lysosomes. The involved disease mechanisms are still incompletely understood, making the design of a rational treatment very difficult. Since the disease is characterized by peripheral inflammation and neuroinflammation and it is shown that extracellular vesicles (EVs) obtained from mesenchymal stromal cells (MSCs) provide immunomodulatory capacities, we tested the potential of MSC-EV preparations to alter NPC1 disease pathology. Here, we show that the administration of an MSC-EV preparation with in vitro and in vivo confirmed immune modulatory capabilities is able to reduce the inflammatory state of peripheral organs and different brain regions of NPC1-diseased mice almost to normal levels. Moreover, a reduction of foamy cells in different peripheral organs was observed upon MSC-EV treatment of NPC1−/− mice. Lastly, the treatment was able to decrease microgliosis and astrogliosis, typical features of NPC1 patients that lead to neurodegeneration. Altogether, our results reveal the therapeutic potential of MSC-EVs as treatment for the genetic neurovisceral lipid storage disease NPC, thereby counteracting both central and peripheral features.
- 8 December 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (12) , 1864
Open AccessAnti-Inflammatory Mesenchymal Stromal Cell-Derived Extracellular Vesicles Improve Pathology in Niemann–Pick Type C Disease
Niemann–Pick type C (NPC) disease is a rare neurovisceral lipid storage disease with progressive neurodegeneration, leading to premature death. The disease is caused by loss-of-function mutations either in the NPC1 or NPC2 gene which results in lipid accumulation in the late endosomes and lysosomes. The involved disease mechanisms are still incompletely understood, making the design of a rational treatment very difficult. Since the disease is characterized by peripheral inflammation and neuroinflammation and it is shown that extracellular vesicles (EVs) obtained from mesenchymal stromal cells (MSCs) provide immunomodulatory capacities, we tested the potential of MSC-EV preparations to alter NPC1 disease pathology. Here, we show that the administration of an MSC-EV preparation with in vitro and in vivo confirmed immune modulatory capabilities is able to reduce the inflammatory state of peripheral organs and different brain regions of NPC1-diseased mice almost to normal levels. Moreover, a reduction of foamy cells in different peripheral organs was observed upon MSC-EV treatment of NPC1−/− mice. Lastly, the treatment was able to decrease microgliosis and astrogliosis, typical features of NPC1 patients that lead to neurodegeneration. Altogether, our results reveal the therapeutic potential of MSC-EVs as treatment for the genetic neurovisceral lipid storage disease NPC, thereby counteracting both central and peripheral features.
- Open Access
- 20 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21) , 11328
Gastric Helicobacter suis Infection Partially Protects against Neurotoxicity in A 6-OHDA Parkinson’s Disease Mouse Model
The exact etiology of Parkinson’s disease (PD) remains largely unknown, but more and more research suggests the involvement of the gut microbiota. Interestingly, idiopathic PD patients were shown to have at least a 10 times higher prevalence of Helicobacter suis (H. suis) DNA in gastric biopsies compared to control patients. H. suis is a zoonotic Helicobacter species that naturally colonizes the stomach of pigs and non-human primates but can be transmitted to humans. Here, we investigated the influence of a gastric H. suis infection on PD disease progression through a 6-hydroxydopamine (6-OHDA) mouse model. Therefore, mice with either a short- or long-term H. suis infection were stereotactically injected with 6-OHDA in the left striatum and sampled one week later. Remarkably, a reduced loss of dopaminergic neurons was seen in the H. suis/6-OHDA groups compared to the control/6-OHDA groups. Correspondingly, motor function of the H. suis-infected 6-OHDA mice was superior to that in the non-infected 6-OHDA mice. Interestingly, we also observed higher expression levels of antioxidant genes in brain tissue from H. suis-infected 6-OHDA mice, as a potential explanation for the reduced 6-OHDA-induced cell loss. Our data support an unexpected neuroprotective effect of gastric H. suis on PD pathology, mediated through changes in oxidative stress.
- 20 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21) , 11328
Open AccessGastric Helicobacter suis Infection Partially Protects against Neurotoxicity in A 6-OHDA Parkinson’s Disease Mouse Model
The exact etiology of Parkinson’s disease (PD) remains largely unknown, but more and more research suggests the involvement of the gut microbiota. Interestingly, idiopathic PD patients were shown to have at least a 10 times higher prevalence of Helicobacter suis (H. suis) DNA in gastric biopsies compared to control patients. H. suis is a zoonotic Helicobacter species that naturally colonizes the stomach of pigs and non-human primates but can be transmitted to humans. Here, we investigated the influence of a gastric H. suis infection on PD disease progression through a 6-hydroxydopamine (6-OHDA) mouse model. Therefore, mice with either a short- or long-term H. suis infection were stereotactically injected with 6-OHDA in the left striatum and sampled one week later. Remarkably, a reduced loss of dopaminergic neurons was seen in the H. suis/6-OHDA groups compared to the control/6-OHDA groups. Correspondingly, motor function of the H. suis-infected 6-OHDA mice was superior to that in the non-infected 6-OHDA mice. Interestingly, we also observed higher expression levels of antioxidant genes in brain tissue from H. suis-infected 6-OHDA mice, as a potential explanation for the reduced 6-OHDA-induced cell loss. Our data support an unexpected neuroprotective effect of gastric H. suis on PD pathology, mediated through changes in oxidative stress.
- 15 May 2021
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 8 (6) , 961-962
Reversible Drug‐Induced Pisa Syndrome Due to a Cholinesterase Inhibitor
- 15 May 2021
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 8 (6) , 961-962
Reversible Drug‐Induced Pisa Syndrome Due to a Cholinesterase Inhibitor